Med. praxi. 2024;21(2):79-83 | DOI: 10.36290/med.2024.013

Optimal heart rate value - not only hypertensive patients

MUDr. Petra Vysočanová
Interní kardiologická klinika, FN Brno, Masarykova univerzita Brno

Heart rate (HR) is related to a number of diseases, especially cardiovascular (CVD). Every 10 beats/min increases in TF is associated with an 8% increased risk of CV disease. In individuals with hypertension, a resting HR > 80/min is a CV risk factor. According to the new results, nighttime TF is the most sensitive, when the threshold value for the increase in mortality in patients with hypertension is 90/min. b­‑blockers can be used to reduce TF in patients with hypertension, while according to current Czech recommendations, b­‑blockers are suitable for hypertensive patients with TF ≥75/min. It is possible to administer them in any step of the treatment of hypertension, both in monotherapy and in combinations, and they are recommended in about 150 described clinical situations. TF >75/min is present in up to 30% of hypertensive patients, so it is good to monitor its value and, in indicated cases, include β­‑blockers in the treatment. When administering them, there is no need to worry about limiting physical performance, worsening symptoms of chronic obstructive pulmonary disease or erectile dysfunction. On the contrary, they are beneficial for hypertensive patients with obstructive sleep apnea, migraine, depression/anxiety or postmenopausal women. The described benefit can be achieved with cardioselective β‑blockers. The highest β1-selectivity was demonstrated by bisoprolol, which also has the advantage of metabolic neutrality. Bisoprolol + amlodipine or bisoprolol + perindopril can be used for the recommended fixed double combination treatment. The fixed combination of bisoprolol + perindopril demonstrated an average reduction of blood pressure by 28/14 mmHg and TF by 17/min within 1 month of initiation.

Keywords: tepová frekvence, β­‑blokátory, hypertenze, antihypertenziva, bisoprolol, perindopril, obstrukční spánková apnoe, erektilní dysfunkce, fixní kombinace antihypertenziv.

Accepted: April 22, 2024; Published: May 17, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vysočanová P. Optimal heart rate value - not only hypertensive patients. Med. praxi. 2024;21(2):79-83. doi: 10.36290/med.2024.013.
Download citation

References

  1. Williams B, Mancia G, Spiering W, et al; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. Go to original source... Go to PubMed...
  2. Levy RL, White PD, Stroud WD, et al. Transient tachycardia: Prognostic significance alone and in association with transient hypertension. Journal of the American Medical Association. 1945;129(9):585-588. Go to original source...
  3. Julius S, Palatini P, Kjeldsen SE, et al. Usefulness of heart rate to predict cardiac events in treated patients with high­‑risk systemic hypertension. Am J Cardiol. 2012 Mar 1;109(5):685-692. Go to original source... Go to PubMed...
  4. Böhm M, Schwantke I, Mahfoud F, et al. Association of clinic and ambulatory heart rate parameters with mortality in hypertension. J Hypertens. 2020 Dec;38(12):2416-2426. Go to original source... Go to PubMed...
  5. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071. Go to original source... Go to PubMed...
  6. Widimský J jr, Filipovský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2017. Doporučení České společnosti pro hypertenzi. Vnitr Lek. 2018;64(7-8):771-796.
  7. Benetos A, Rudnichi A, Thomas F, et al. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension. 1999 Jan;33(1):44-52. Go to original source... Go to PubMed...
  8. Foch C, Allignol A, Hohenberger T, et al. Effectiveness of bisoprolol versus other β­‑blockers and other antihypertensive classes: a cohort study in the Clinical Practice Research Datalink. J Comp Eff Res. 2022 Apr;11(6):423-436. Go to original source... Go to PubMed...
  9. Mitchell BL, Davison K, Parfitt G, et al. Physiological and Perceived Exertion Responses during Exercise: Effect of β­‑blockade. Med Sci Sports Exerc. 2019 Apr;51(4):782-791. Go to original source... Go to PubMed...
  10. Priel E, Wahab M, Mondal T, et al. The Impact of beta blockade on the cardio­‑respiratory system and symptoms during exercise. Curr Res Physiol. 2021 Oct 28;4:235-242. Go to original source... Go to PubMed...
  11. Svedmyr S, Hedner J, Bonsignore MR, et al; European Sleep Apnea Database (ESADA) study group (full collaborator list in E­‑supplement). Hypertension treatment in patients with sleep apnea from the European Sleep Apnea Database (ESADA) cohort - towards precision medicine. J Sleep Res. 2023 Aug;32(4):e13811. Go to original source... Go to PubMed...
  12. Dorow P, Bethge H, Tnnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol. 1986;31(2):143-147. Go to original source... Go to PubMed...
  13. Etminan M, Jafari S, Carleton B, FitzGerald JM. Beta‑blocker use and COPD mortality: a systematic review and meta‑analysis. BMC Pulm Med. 2012 Sep 4;12:48. Go to original source... Go to PubMed...
  14. Wellstein A, Palm D, Belz GG. Affinity and selectivity of beta­‑adrenoceptor antagonists in vitro. J Cardiovasc Pharmacol. 1986;8 Suppl 11:S36-40. doi: 10.1097/00005344-198511001-00006. PMID: 2439796. Go to original source... Go to PubMed...
  15. Wellstein A, Palm D, Belz GG, et al. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta­‑adrenoceptor occupancy. Eur Heart J. 1987 Dec;8 Suppl M:3-8. doi: 10.1093/eurheartj/8.suppl_m.3. PMID: 2897299. Go to original source... Go to PubMed...
  16. Fogari R, Zoppi A, Tettamanti F, et al. Beta­‑blocker effects on plasma lipids in antihypertensive therapy: importance of the duration of treatment and the lipid status before treatment. J Cardiovasc Pharmacol. 1990;16 Suppl 5:S76-80. PMID: 11527140. Go to original source...
  17. Jackson JL, Kuriyama A, Kuwatsuka Y, et al. Beta­‑blockers for the prevention of headache in adults, a systematic review and meta­‑analysis. PLoS One. 2019 Mar 20;14(3):e0212785. Go to original source... Go to PubMed...
  18. Baker FC, Forouzanfar M, Goldstone A, et al. Changes in heart rate and blood pressure during nocturnal hot flashes associated with and without awakenings. Sleep. 2019 Oct 21;42(11):zsz175. Go to original source... Go to PubMed...
  19. Yamashita T, Ikeda T, Akita Y. Comparison of heart rate reduction effect and safety between bisoprolol transdermal patch and bisoprolol fumarate oral formulation in Japanese patients with persistent/permanent atrial fibrillation (BISONO­‑AF study). J Cardiol. 2019 May;73(5):386-393. Go to original source... Go to PubMed...
  20. Fogari R, Zoppi A, Corradi L, et al. Comparison of bisoprolol and diazepam in the treatment of cardiac neurosis. Cardiovasc Drugs Ther. 1992 Jun;6(3):249-253. Go to original source... Go to PubMed...
  21. Battes LC, Pedersen SS, Oemrawsingh RM, et al. Beta blocker therapy is associated with reduced depressive symptoms 12 months post percutaneous coronary intervention. J Affect Disord. 2012 Feb; 136(3):751-757. Go to original source... Go to PubMed...
  22. Katayose D. Yokukansankachimpihange therapy fortified with bisoprolol and lifestyle changes in a patient intolerant to antihypertensive agents. Traditional & Kampo Medicine. 2022;10(1):61-66. Go to original source...
  23. Lutai MI, Golikova IP. The Effectiveness of Treatment of Patients With Stable Coronary Heart Disease and Concomitant Arterial Hypertension: The Results of a Multicenter Study PRESTOL. Ukrainian Cardiology Magazine. 2019 Apr;26(1):19-30. doi:10.31928/1608-635X-2019. 1. 1930. Go to original source...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.